Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
Mayo Clinic
Ohio State University Comprehensive Cancer Center
University of Alabama at Birmingham
Mayo Clinic
Thomas Jefferson University
City of Hope Medical Center
Fox Chase Cancer Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
University of Pittsburgh
Wake Forest University Health Sciences
Stanford University
Stanford University
Peter MacCallum Cancer Centre, Australia
University of Zurich
Fred Hutchinson Cancer Center
University of Michigan Rogel Cancer Center
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
University of California, San Francisco
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
University of Wisconsin, Madison
Northwestern University
Mayo Clinic
Case Comprehensive Cancer Center
Swiss Cancer Institute
City of Hope Medical Center
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NYU Langone Health
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Massachusetts General Hospital
University of Louisville
Alliance for Clinical Trials in Oncology
Case Comprehensive Cancer Center
City of Hope Medical Center
Indiana University
Indiana University
Barbara Ann Karmanos Cancer Institute
Ohio State University Comprehensive Cancer Center